These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 31481106)

  • 1. A multicenter randomized, double-blind, placebo-controlled pilot study to assess the efficacy and safety of riociguat in systemic sclerosis-associated digital ulcers.
    Nagaraja V; Spino C; Bush E; Tsou PS; Domsic RT; Lafyatis R; Frech T; Gordon JK; Steen VD; Khanna D
    Arthritis Res Ther; 2019 Sep; 21(1):202. PubMed ID: 31481106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RISE-SSc: Riociguat in diffuse cutaneous systemic sclerosis.
    Distler O; Pope J; Denton C; Allanore Y; Matucci-Cerinic M; de Oliveira Pena J; Khanna D
    Respir Med; 2017 Jan; 122 Suppl 1():S14-S17. PubMed ID: 27746061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study.
    Nathan SD; Behr J; Collard HR; Cottin V; Hoeper MM; Martinez FJ; Corte TJ; Keogh AM; Leuchte H; Mogulkoc N; Ulrich S; Wuyts WA; Yao Z; Boateng F; Wells AU
    Lancet Respir Med; 2019 Sep; 7(9):780-790. PubMed ID: 31416769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Macitentan on the Development of New Ischemic Digital Ulcers in Patients With Systemic Sclerosis: DUAL-1 and DUAL-2 Randomized Clinical Trials.
    Khanna D; Denton CP; Merkel PA; Krieg T; Le Brun FO; Marr A; Papadakis K; Pope J; Matucci-Cerinic M; Furst DE; ;
    JAMA; 2016 May; 315(18):1975-88. PubMed ID: 27163986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial.
    Matucci-Cerinic M; Denton CP; Furst DE; Mayes MD; Hsu VM; Carpentier P; Wigley FM; Black CM; Fessler BJ; Merkel PA; Pope JE; Sweiss NJ; Doyle MK; Hellmich B; Medsger TA; Morganti A; Kramer F; Korn JH; Seibold JR
    Ann Rheum Dis; 2011 Jan; 70(1):32-8. PubMed ID: 20805294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): open-label, long-term extension of a phase 2b, randomised, placebo-controlled trial.
    Distler O; Allanore Y; Denton CP; Kuwana M; Matucci-Cerinic M; Pope JE; Atsumi T; Bečvář R; Czirják L; Hachulla E; Ishii T; Ishikawa O; Johnson SR; De Langhe E; Stagnaro C; Riccieri V; Schiopu E; Silver RM; Smith V; Steen V; Stevens W; Szücs G; Truchetet ME; Wosnitza M; Laapas K; Kramer F; Khanna D
    Lancet Rheumatol; 2023 Nov; 5(11):e660-e669. PubMed ID: 38251533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Riociguat in patients with sickle cell disease and hypertension or proteinuria (STERIO-SCD): a randomised, double-blind, placebo controlled, phase 1-2 trial.
    Gladwin MT; Gordeuk VR; Desai PC; Minniti C; Novelli EM; Morris CR; Ataga KI; De Castro L; Curtis SA; El Rassi F; Ford HJ; Harrington T; Klings ES; Lanzkron S; Liles D; Little J; Nero A; Smith W; Taylor JG; Baptiste A; Hagar W; Kanter J; Kinzie A; Martin T; Rafique A; Telen MJ; Lalama CM; Kato GJ; Abebe KZ
    Lancet Haematol; 2024 May; 11(5):e345-e357. PubMed ID: 38554715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomised placebo-controlled double-blind trial to assess the safety of intramuscular administration of allogeneic mesenchymal stromal cells for digital ulcers in systemic sclerosis: the MANUS Trial protocol.
    van Rhijn-Brouwer FCC; Gremmels H; Fledderus JO; Schuurman AH; Bonte-Mineur F; Vonk MC; Voskuyl AE; de Vries-Bouwstra JK; Coert JH; Radstake TRDJ; van Laar JM; Verhaar MC;
    BMJ Open; 2018 Aug; 8(8):e020479. PubMed ID: 30127049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study.
    Bonderman D; Ghio S; Felix SB; Ghofrani HA; Michelakis E; Mitrovic V; Oudiz RJ; Boateng F; Scalise AV; Roessig L; Semigran MJ;
    Circulation; 2013 Jul; 128(5):502-11. PubMed ID: 23775260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Riociguat for the treatment of Phe508del homozygous adults with cystic fibrosis.
    Derichs N; Taylor-Cousar JL; Davies JC; Fajac I; Tullis E; Nazareth D; Downey DG; Rosenbluth D; Malfroot A; Saunders C; Jensen R; Solomon GM; Vermeulen F; Kaiser A; Willmann S; Saleh S; Droebner K; Sandner P; Bear CE; Hoffmann A; Ratjen F; Rowe SM;
    J Cyst Fibros; 2021 Nov; 20(6):1018-1025. PubMed ID: 34419414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of rituximab in systemic sclerosis (DESIRES): open-label extension of a double-blind, investigators-initiated, randomised, placebo-controlled trial.
    Ebata S; Yoshizaki A; Oba K; Kashiwabara K; Ueda K; Uemura Y; Watadani T; Fukasawa T; Miura S; Yoshizaki-Ogawa A; Okiyama N; Kodera M; Hasegawa M; Sato S
    Lancet Rheumatol; 2022 Aug; 4(8):e546-e555. PubMed ID: 38294008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Riociguat for the Treatment of Raynaud's Phenomenon: A Single-Dose, Double-Blind, Randomized, Placebo-Controlled Cross-Over Pilot Study (DIGIT).
    Huntgeburth M; Kießling J; Weimann G; Wilberg V; Saleh S; Hunzelmann N; Rosenkranz S
    Clin Drug Investig; 2018 Nov; 38(11):1061-1069. PubMed ID: 30238433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial.
    Khanna D; Allanore Y; Denton CP; Kuwana M; Matucci-Cerinic M; Pope JE; Atsumi T; Bečvář R; Czirják L; Hachulla E; Ishii T; Ishikawa O; Johnson SR; De Langhe E; Stagnaro C; Riccieri V; Schiopu E; Silver RM; Smith V; Steen V; Stevens W; Szücs G; Truchetet ME; Wosnitza M; Laapas K; de Oliveira Pena J; Yao Z; Kramer F; Distler O
    Ann Rheum Dis; 2020 May; 79(5):618-625. PubMed ID: 32299845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study.
    Hachulla E; Hatron PY; Carpentier P; Agard C; Chatelus E; Jego P; Mouthon L; Queyrel V; Fauchais AL; Michon-Pasturel U; Jaussaud R; Mathian A; Granel B; Diot E; Farge-Bancel D; Mekinian A; Avouac J; Desmurs-Clavel H; Clerson P;
    Ann Rheum Dis; 2016 Jun; 75(6):1009-15. PubMed ID: 25995322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
    Abou-Raya A; Abou-Raya S; Helmii M
    J Rheumatol; 2008 Sep; 35(9):1801-8. PubMed ID: 18709692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular biomarkers and digital ulcerations in systemic sclerosis: results from a randomized controlled trial of oral treprostinil (DISTOL-1).
    Mecoli CA; Perin J; Van Eyk JE; Zhu J; Fu Q; Allmon AG; Rao Y; Zeger S; Wigley FM; Hummers LK; Shah AA
    Clin Rheumatol; 2020 Apr; 39(4):1199-1205. PubMed ID: 31858338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Riociguat for Sarcoidosis-Associated Pulmonary Hypertension: Results of a 1-Year Double-Blind, Placebo-Controlled Trial.
    Baughman RP; Shlobin OA; Gupta R; Engel PJ; Stewart JI; Lower EE; Rahaghi FF; Zeigler J; Nathan SD
    Chest; 2022 Feb; 161(2):448-457. PubMed ID: 34363816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Praliciguat on Peak Rate of Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction: The CAPACITY HFpEF Randomized Clinical Trial.
    Udelson JE; Lewis GD; Shah SJ; Zile MR; Redfield MM; Burnett J; Parker J; Seferovic JP; Wilson P; Mittleman RS; Profy AT; Konstam MA
    JAMA; 2020 Oct; 324(15):1522-1531. PubMed ID: 33079154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial.
    Hoeper MM; Al-Hiti H; Benza RL; Chang SA; Corris PA; Gibbs JSR; Grünig E; Jansa P; Klinger JR; Langleben D; McLaughlin VV; Meyer GMB; Ota-Arakaki J; Peacock AJ; Pulido T; Rosenkranz S; Vizza CD; Vonk-Noordegraaf A; White RJ; Chang M; Kleinjung F; Meier C; Paraschin K; Ghofrani HA; Simonneau G;
    Lancet Respir Med; 2021 Jun; 9(6):573-584. PubMed ID: 33773120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Riociguat for the treatment of pulmonary arterial hypertension.
    Ghofrani HA; Galiè N; Grimminger F; Grünig E; Humbert M; Jing ZC; Keogh AM; Langleben D; Kilama MO; Fritsch A; Neuser D; Rubin LJ;
    N Engl J Med; 2013 Jul; 369(4):330-40. PubMed ID: 23883378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.